Described is the construction of a large array of releasable microstructures (micropallets) along with screening and isolation protocols for sorting rare, approximately 1 in 10,000, cancer stem cells (CSCs) from a heterogeneous cell population. A 10.1 × 7.1 cm array of micropallets (50 × 50 × 75 μm structures and 25 μm micropallet gap) was fabricated on a large glass substrate, providing an array of approximately 1.3 million releasable microstructures. Image analysis algorithms were developed to permit array screening for identification of fluorescently labeled cells in less than 15 min using an epifluorescent wide-field microscope with a computer controlled translational stage. Device operation was tested by culturing HeLa cells transfected with green fluorescent protein (GFP) admixed with wild-type HeLa cells at ratios of 1:10(4) to 1:10(6) on the array followed by screening to identify flourescent cells. Micropallets containing cells of interest were then selectively released by a focused laser pulse and collected on a numbered poly(dimethylsiloxane) (PDMS) substrate with high viability. A direct comparison of this technology with fluorescence-activated cell sorting (FACS) demonstrated that micropallet arrays offered enhanced post sorting purity (100%), yield (100%), and viability (94-100%) for rare cell isolation. As a demonstration of the technology's value, pancreatic tumor cells from Panc-1 cell lines and patient-derived xenografts were screened for the presence of CD24, CD44, and CD326: surface markers of pancreatic CSCs. Following cell isolation and culture, 63 ± 23% of the isolated Panc-1 cells and 35% of sorted human xenograft cells formed tumor spheroids retaining high expression levels of CD24, CD44, and CD326. The ability to isolate rare cells from relatively small sample sizes will facilitate our understanding of cell biology and the development of new therapeutic strategies.
Described is the construction of a large array of releasable microstructures (micropallets) along with screening and isolation protocols for sorting rare, approximately 1 in 10,000, n class="Disease">cancer stem cells (CSCs) from a heterogeneous cell populationpan>. A 10.1 × 7.1 cm array of micropallets (50 × 50 × 75 μm structures anpan>d 25 μm micropallet gap) was fabricated onpan> a large glass substrate, providinpan>g anpan> array of approximately 1.3 millionpan> releasable microstructures. Image anpan>alysis algorithms were developed to permit array screeninpan>g for identificationpan> of fluorescently labeled cells inpan> less thanpan> 15 minpan> usinpan>g anpan> epifluorescent wide-field microscope with a computer conpan>trolled tranpan>slationpan>al stage. Device operationpan> was tested by culturinpan>g pan> class="CellLine">HeLa cells transfected with green fluorescent protein (GFP) admixed with wild-type HeLa cells at ratios of 1:10(4) to 1:10(6) on the array followed by screening to identify flourescent cells. Micropallets containing cells of interest were then selectively released by a focused laser pulse and collected on a numbered poly(dimethylsiloxane) (PDMS) substrate with high viability. A direct comparison of this technology with fluorescence-activated cell sorting (FACS) demonstrated that micropallet arrays offered enhanced post sorting purity (100%), yield (100%), and viability (94-100%) for rare cell isolation. As a demonstration of the technology's value, pancreatic tumor cells from Panc-1 cell lines and patient-derived xenografts were screened for the presence of CD24, CD44, and CD326: surface markers of pancreatic CSCs. Following cell isolation and culture, 63 ± 23% of the isolated Panc-1 cells and 35% of sorted human xenograft cells formed tumor spheroids retaining high expression levels of CD24, CD44, and CD326. The ability to isolate rare cells from relatively small sample sizes will facilitate our understanding of cell biology and the development of new therapeutic strategies.
Authors: G Vona; A Sabile; M Louha; V Sitruk; S Romana; K Schütze; F Capron; D Franco; M Pazzagli; M Vekemans; B Lacour; C Bréchot; P Paterlini-Bréchot Journal: Am J Pathol Date: 2000-01 Impact factor: 4.307
Authors: Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke Journal: Proc Natl Acad Sci U S A Date: 2003-03-10 Impact factor: 11.205
Authors: K J Luzzi; I C MacDonald; E E Schmidt; N Kerkvliet; V L Morris; A F Chambers; A C Groom Journal: Am J Pathol Date: 1998-09 Impact factor: 4.307
Authors: Robert T Krivacic; Andras Ladanyi; Douglas N Curry; H B Hsieh; Peter Kuhn; Danielle E Bergsrud; Jane F Kepros; Todd Barbera; Michael Y Ho; Lan Bo Chen; Richard A Lerner; Richard H Bruce Journal: Proc Natl Acad Sci U S A Date: 2004-07-12 Impact factor: 11.205
Authors: Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes Journal: N Engl J Med Date: 2004-08-19 Impact factor: 91.245
Authors: Alex Panaccione; Michael T Chang; Beatrice E Carbone; Yan Guo; Christopher A Moskaluk; Renu K Virk; Luis Chiriboga; Manju L Prasad; Benjamin Judson; Saral Mehra; Wendell G Yarbrough; Sergey V Ivanov Journal: Clin Cancer Res Date: 2016-04-15 Impact factor: 12.531
Authors: José E Belizário; Beatriz A Sangiuliano; Marcela Perez-Sosa; Jennifer M Neyra; Dayson F Moreira Journal: Front Pharmacol Date: 2016-09-29 Impact factor: 5.810
Authors: Trisha M Westerhof; Wesley A Cox-Muranami; Guann-Pyng Li; Mark Bachman; Hung Fan; Edward L Nelson Journal: Sci Rep Date: 2017-10-12 Impact factor: 4.379